Product Information
CLINDA-TRETINOIN 1.2%-0.025% is a generic product labeled by Solaris Pharma Corporation, priced at $4.3119 per GM under NDC 73473030630. Its NADAC has been published 225 times since Jun 15, 2022.
FDA first approved this application on Feb 10, 2022. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
10; .25 mg/g; mg/g
Manufacturer
Solaris Pharma CorporationNDC
73473030630
Classification
Generic
Dosage Form
GEL
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
CLINDAMYCIN PHOSPHATE; TRETINOINApproval Type
Generic (ANDA)
FDA Application
ANDA212845FDA Approved
2/10/2022
TE Code
AB2
On Market Since
1/3/2025
Pharmacological Classes
Price Statistics
The NADAC for CLINDA-TRETINOIN 1.2%-0.025% has been published 225 times since Jun 15, 2022, and over the history we have for it it has declined 27.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.3119 per GM |
|---|---|
| All-time high | $7.5670 (Oct 11, 2023) |
| All-time low | $4.3119 (Sep 23, 2026) |
| 52-week high | $4.9717 |
| 52-week low | $4.3119 |
| Median price | $5.5383 |
| Average price | $5.6329 |
| Largest weekly change | -31.8% (Dec 20, 2023) |
| Weeks tracked | 225 |
| Tracking since | Jun 15, 2022 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 19% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Solaris Pharma Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
clindamycin phosphate and tretinoin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Lincosamide Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CLINDA-TRETINOIN 1.2%-0.025%?
The current National Average Drug Acquisition Cost (NADAC) for CLINDA-TRETINOIN 1.2%-0.025%, manufactured by Solaris Pharma Corporation, is $4.3119 per GM (NDC 73473030630), effective Sep 30, 2026.
How has the price of CLINDA-TRETINOIN 1.2%-0.025% changed over time?
Over the history we have for it, the NADAC for CLINDA-TRETINOIN 1.2%-0.025% has declined 27.7%. It has been tracked across 225 weekly CMS publications since Jun 15, 2022.
What are the highest and lowest recorded NADAC prices for CLINDA-TRETINOIN 1.2%-0.025%?
Since Jun 15, 2022, the NADAC for CLINDA-TRETINOIN 1.2%-0.025% has ranged from a low of $4.3119 (Sep 23, 2026) to a high of $7.5670 (Oct 11, 2023), with a median of $5.5383 per GM.
Are there cheaper alternatives to CLINDA-TRETINOIN 1.2%-0.025%?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CLINDA-TRETINOIN 1.2%-0.025%, is $3.5063 per GM — about 19% below CLINDA-TRETINOIN 1.2%-0.025%.
Who manufactures CLINDA-TRETINOIN 1.2%-0.025%?
CLINDA-TRETINOIN 1.2%-0.025% (NDC 73473030630) is labeled by Solaris Pharma Corporation, and CMS classifies it as a generic product.